CAS 198470-84-7|parecoxib
| Common Name | parecoxib | ||
|---|---|---|---|
| CAS Number | 198470-84-7 | Molecular Weight | 370.422 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C19H18N2O4S | Melting Point | 148.9-151° |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS08 | Signal Word | Warning |
Names
| Name | parecoxib |
|---|---|
| Synonym | More Synonyms |
parecoxib BiologicalActivity
| Description | Parecoxib is a potent and selective COX-2 inhibitor.IC50 value:Target: COX-2in vitro: The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells and rat brain tissue [1].in vivo: Adult male Sprague-Dawley rats were administered parecoxib (10 or 30 mg kg(-1), IP) or isotonic saline twice a day starting 24 h after middle cerebral artery occlusion (MCAO) for three consecutive days [2]. The selective COX-2 inhibitor parecoxib was delivered 20 min before or 20 min after the incision by intraperitoneal injection. Pretreatment with parecoxib markedly attenuated the pain hypersensitivity induced by incision [3]. |
|---|---|
| Related Catalog | Research Areas >>Inflammation/Immunology |
| Target | COX-2 |
| References | [1]. Ye Z, et al. Delayed administration of parecoxib, a specific COX-2 inhibitor, attenuated postischemic neuronal apoptosis by phosphorylation Akt and GSK-3β. Neurochem Res. 2012 Feb;37(2):321-9. [2]. Schr?der H, et al. Parecoxib and its metabolite valdecoxib directly interact with cannabinoid binding sites in CB1-expressing HEK 293 cells and rat brain tissue. Neurochem Int. 2011 Jan;58(1):9-13. [3]. Guo YJ, et al. Analgesic effects of the COX-2 inhibitor parecoxib on surgical pain through suppression of spinal ERK signaling. Exp Ther Med. 2013 Jul;6(1):275-279. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Melting Point | 148.9-151° |
| Molecular Formula | C19H18N2O4S |
| Molecular Weight | 370.422 |
| Exact Mass | 370.098724 |
| PSA | 101.14000 |
| LogP | 1.72 |
| Index of Refraction | 1.580 |
| InChIKey | TZRHLKRLEZJVIJ-UHFFFAOYSA-N |
| SMILES | CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1 |
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H361d-H373 |
| Precautionary Statements | P281 |
| Hazard Codes | Xn,N |
| Risk Phrases | 63-48/22-51/53 |
| Safety Phrases | 36/37-61 |
| RIDADR | NONH for all modes of transport |
| RTECS | TX1478700 |
Articles9
More Articles| Bsm1 vitamin D receptor polymorphism and calcium homeostasis following bariatric surgery. J. Invest. Surg. 28(1) , 8-17, (2015) To evaluate the association between the Bsm1 vitamin D receptor polymorphism and the calcium-vitamin D-parathormone axis following bariatric surgery.This cross-sectional study included 86 morbidly obe... | |
| The effect of TSPP-mediated photodynamic therapy and Parecoxib in experimental tumours. Life Sci. 117(2) , 75-83, (2015) The study investigated the effects of the combined treatment Parecoxib (Pcox) and 5,10,15,20-tetra-sulphonato-phenyl-porphyrin(TSPP)-mediated photodynamic therapy on Walker 256 carcinosarcoma.Five gro... | |
| Prostaglandin-dependent modulation of dopaminergic neurotransmission elicits inflammation-induced aversion in mice. J. Clin. Invest. 126 , 695-705, (2016) Systemic inflammation causes malaise and general feelings of discomfort. This fundamental aspect of the sickness response reduces the quality of life for people suffering from chronic inflammatory dis... |
Synonyms
| N-{[4-(5-Methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide |
| N-[[4-[5-methyl-3-phenylisoxazol-4-yl]phenyl]sulfonyl]propanamide |
| parecoxib |
| N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-propanamide |
| 4-[4-(N-propionylsulfamoyl)-phenyl]-5-methyl-3-phenyl-isoxazole |
| N-propanoyl-4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide |
| Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]- |
| N-[[4-[5-methyl-3-phenylisoxazol-4-yl]phenyl]sulfonyl]acetamide |
| Dynastat |
